EyePoint Pharmaceuticals Drops 10.38% on Q2 Loss, Clinical Progress

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) experienced a significant drop of 10.38% in pre-market trading on August 6, 2025, following the release of its second-quarter financial results and recent corporate developments.

EyePoint Pharmaceuticals, Inc. has made substantial progress in its clinical trials for DURAVYU™, an innovative sustained delivery treatment for VEGF-mediated retinal diseases. The company completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized. The LUGANO and LUCIA trials, which are double-masked non-inferiority trials, rapidly enrolled in seven months, highlighting strong physician and patient interest. Topline 56-week data for LUGANO is on track for readout in mid-2026, with LUCIA data to closely follow. The company's Northbridge, MA commercial manufacturing facility is now operational, with DURAVYU registration batches underway. EyePoint's cash position of $256 million as of June 30, 2025, provides a cash runway into 2027, beyond the topline data for both Phase 3 wet AMD trials.

Despite the positive developments in clinical trials, EyePoint reported a net loss of $59.4 million for the second quarter ended June 30, 2025, compared to a net loss of $30.8 million in the same period last year. The decrease in net revenue from license and royalties, primarily driven by lower recognition of deferred revenue related to the Company’s 2023 agreement for the license of YUTIQ® product rights, contributed to the financial loss. Operating expenses increased to $67.6 million, primarily due to higher clinical trial costs related to ongoing DURAVYU™ Phase 3 clinical trials for wet AMD. The company's cash, cash equivalents, and marketable securities totaled $256 million as of June 30, 2025, down from $371 million as of December 31, 2024.